Clearside Biomedical Inc
NASDAQ:CLSD

Watchlist Manager
Clearside Biomedical Inc Logo
Clearside Biomedical Inc
NASDAQ:CLSD
Watchlist
Price: 0.7668 USD -6.39%
Market Cap: 59.2m USD

Clearside Biomedical Inc
Investor Relations

Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.

Show more
Loading

Earnings Calls

2024 Q4
Jan 23, 2025
Show Transcript
Previous
Next
Horizon Bancorp Displays Strong Loan Growth and Optimistic 2025 Outlook
2024 Q4
Jan 23, 2025

In Horizon Bancorp's fourth quarter, total loans grew by $123 million, achieving a 10% annualized growth, driven largely by commercial lending. The company anticipates continued growth, projecting a mid-single-digit increase in 2025, while absorbing a $100 million decline in lower-yielding auto loans. Margin performance also strengthened, with a net interest margin of 2.97%, expected to improve to about 3.15-3.20% by year-end. Horizon aims to keep noninterest expenses steady and targets a tax rate in the mid-teens, indicating strong operational efficiency and long-term value for shareholders.

Show Full Analysis

Management

Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
President, CEO & Director
No Bio Available
Mr. Charles A. Deignan
Chief Financial Officer
No Bio Available
Ms. Jenny R. Kobin
Head of Investor Relations
No Bio Available
Mr. Rick McElheny
Senior Vice President of Corporate Development & Alliance Management
No Bio Available
Mr. Rafael V. Andino
Senior Vice President of Engineering & Manufacturing
No Bio Available
Ms. Susan L. Coultas Ph.D.
Chief Clinical Officer
No Bio Available
Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D.
Chief Medical Officer
No Bio Available

Contacts

Address
GEORGIA
Alpharetta
900 N Point Pkwy Ste 200
Contacts
+16782703631.0
clearsidebio.com